HIV type 2 (HIV-2) was identified in 1985 in Senegal, West Africa, as the second immunodeficiency virus to infect humans [1] [2] [3] . Like HIV type 1 (HIV-1), HIV-2 is known to cause AIDS; however, HIV-2 is comparatively less pathogenic than HIV-1. Since its identification, the epidemic of HIV-2 infection has remained largely confined to West Africa [4] . However, evidence of an HIV-2 epidemic has been reported in India [4] , along with modest prevalence in Europe and the United States [5] . HIV-2 is less transmissible than HIV-1, with a 5-to 10-fold lower rate of heterosexual transmission [6, 7] and a 20-to 30-fold lower rate of mother-to-child transmission [8] [9] [10] . The natural history of HIV-2 infection is distinguished by a longer asymptomatic phase than that of HIV-1 infection [11] , mented. This research was approved as exempt under 45 CFR 46.101(b)(4) by the Institutional Review Board of the Harvard University School of Public Health (EX-02-232).
HIV-2 diagnosis. All patients' serum samples were analyzed for antibody reactivity to whole-virus lysate on HIV-1 and HIV-2 immunoblots to confirm infection. An in-house, whole-virus HIV-1 and HIV-2 immunoblot was performed with a combined-antigen format. Results were interpreted on the basis of World Health Organization recommendations [13] . Recombinant immunoblots that used the highly sensitive recombinant envelope peptides 566 and 996 for HIV-1 and HIV-2, respectively [14] , were run when differentiation between HIV-2 and HIV-1 was required.
In cases in which serological testing could not positively distinguish the infecting virus, confirmation was performed by diagnostic PCR for HIV-1 and HIV-2, as previously described [15, 16] . Diagnostic PCR was performed on PBMC-derived DNA. Primers for HIV-1 env and gag, and HIV-2 env and gag, were used in nested PCR reactions. The specificity of the PCR product was confirmed by Southern blot test.
HIV-2 virus load. Plasma RNA virus load was measured for sequential samples from each subject by means of an inhouse method that has a lower detection limit of 100 copies/ mL and is linear over 4 logs [17] . Briefly, virus was pelleted from 0.5 mL of cryopreserved plasma, and viral genomic RNA was isolated via guanidinium isothiocyanate precipitation followed by alcohol precipitation. Reverse transcriptase-PCR was performed with a GeneAmp rTth RNA PCR kit (Applied Biosystems); primers were used that were specific to gag in the presence of a coamplifying internal control template. Products were quantified by fluorescence-labeled primer read on an ABI 373XL automated sequencer (Applied Biosystems) and were analyzed by Genescan software, version 2.1 (Applied Biosystems).
Data analysis. Clinical, therapeutic, and laboratory results were plotted on individual patient timelines. Disease status was categorized with use of the Centers for Disease Control and Prevention (CDC) revised classification system for HIV infection [18] . CD4 + cell counts and virus loads were analyzed by Stata software, version 6.0 (Stata Institute). These data and their transformations were not normally distributed; therefore, the Wilcoxon rank-sum (Mann-Whitney) test was used for data analyses.
CASE STUDIES
Ten patients are presented in this case series. Demographic and clinical data for each of these patients are given in table figure 1B) . At that time, she presented with thrush, diarrhea, and oral pain. Immunoblot revealed antibody reactivity to pol and env antigens with no reactivity to gag antigens. Lack of reactivity to the p26 core protein has previously been associated with more-rapid disease progression in cases of HIV-2 infection [19] . In counts have remained !250 cells/mL, and his virus loads have remained 14.5 log 10 copies/mL.
Patients 4a and 4b. Patient 4a ( figure 1D ) was a man from Cape Verde, and patient 4b was his female partner. The man received his diagnosis in October 1999 when he was evaluated for neurological symptoms (including aphasia, imbalance, and bowel incontinence). Serological testing results for patient 4a showed HIV-2 env only and were negative for p26. ART was initiated with a combination of lamivudine and zidovudine, and nelfinavir was added in December 1999. The patient's neurological symptoms improved during the course of the year. Treatment with the protease inhibitor (PI) was suspended shortly thereafter for 2 weeks during treatment for an obstruction of the small bowel. In June 2001, nelfinavir was replaced with saquinavir. The patient remained clinically stable, although the patient's HIV-2 virus load did not decrease during therapy.
The patient's partner (patient 4b) was also clinically evaluated and received a diagnosis of HIV-2 infection. The results of an immunoblot demonstrated typical HIV-2 reactivity to all major viral antigens. The patient remained healthy without receiving ART. The patient's virus loads have consistently remained at 2 log 10 copies/mL, and the patient's CD4 + cell counts have consistently been 1800 cells/mL. figure  1E ). Therapy was initiated with a combination of lamivudine and zidovudine and abacavir; it was changed the next year to abacavir, stavudine and didanosine, and ritonavir and indinavir. The patient's virus load increased from 2.5 to 3.5 log 10 copies/ mL during the next year, and the patient's CD4 + cell count increased to 1300 cells/mL. The patient recovered from his opportunistic infections and remained stable through February 2003.
Patient 7. Patient 7 was a man who originally received a diagnosis of infection with HIV-1 in January 1997 ( figure 1F) . ART, consisting of a combination of lamivudine and zidovudine and indinavir, was initiated during the same month. The patient's HIV-1 virus load had remained undetectable through 1999, with CD4 + cell counts of 1200 cells/mL. In November 1999, with the patient's CD4 + cell count decreasing, the NRTIs were replaced with tenofovir. Oral thrush developed in May 2001, and abacavir replaced the tenofovir. HIV-1 virus load remained undetectable throughout, and our laboratory confirmed HIV-2 infection. HIV-2 virus load was measured at 4.88 log 10 copies/mL. In April 2002, ART was changed to stavudine and didanosine and a combination of lopinavir and ritonavir. In June 2002, with continued depressed CD4 + cell counts, therapy was changed, with the PIs being dropped and the addition of tenofovir and efavirenz. Therapy was changed again, in February 2003, to abacavir, saquinavir, and ritonavir. Although the patient is currently asymptomatic, treatment has failed to com-pletely control the patient's virus load or boost his CD4 + cell counts.
Patient 8. Patient 8 was a woman from Sierra Leone who received a diagnosis of HIV-2 infection in March 1999, when she was 14 weeks pregnant. Results of serological testing showed HIV-2 env only. Therapy with a combination of lamivudine and zidovudine was initiated the next month. The patient received an intravenous infusion of zidovudine (1350 mg) during labor in October 1999. The patient was enrolled in ACTG protocol 316 [20] and received either 200 mg of nevirapine or placebo during labor. ART was discontinued postpartum because of her high CD4 + cell counts and undetectable HIV-2 virus load. In June 2003, the patient's virus load was 3.06 log 10 copies/mL. 
RESULTS
Our laboratory has aided in the diagnosis and monitoring of 120 cases of HIV-2 infection in people living in the United States. We have selected 10 patients to describe on the basis of the availability of follow-up data, clinical histories, and laboratory correlates. We compared median CD4 + cell count and median virus load values between sick and healthy individuals. We stratified our study population by clinical status: patients who were identified as CDC class A1 and A2 were considered asymptomatic, and patients identified as belonging to the remaining CDC classes were considered symptomatic.
Median CD4 + cell counts were lower among symptomatic individuals (median CD4 + cell count, 175 cells/mL; range, 53-286 cells/mL) compared with the asymptomatic group (median CD4 + cell count, 639 cells/mL; range, 302-1012 cells/mL). The difference between the medians was found to be statistically significant ( , by Wilcoxon rank-sum test). P ! .0167 Median HIV-2 virus loads of symptomatic and asymptomatic individuals were compared. Asymptomatic individuals demonstrated a lower median virus load (median virus load, 2.498 log 10 copies/mL; range, 1.699-3.846 log 10 copies/mL), compared with symptomatic individuals (median virus load, 4.679 log 10 copies/mL; range, 3.018-4.917 log 10 copies/mL). The difference between the medians fell slightly short of statistical significance ( , by Wilcoxon rank-sum test). P p .0527 Three individuals were asymptomatic (patients 4b, 8, and 9) and had normal CD4 + cell counts and undetectable or low virus loads. Patients 8 and 9 were provided with ART. Patient 8 received ∼5 months of treatment with a combination of lamivudine and zidovudine during her pregnancy. Seven of the individuals whom we studied were symptomatic with HIV disease (patients 1, 2, 3, 4a, 5, 6, and 7) . All of these individuals exhibited depressed CD4 + cell counts and high virus loads. The symptomatic individuals were evaluated for increases in CD4 + cell count and reduction of virus load. Three of 7 symptomatic patients (patients 1, 4, and 6) demonstrated improvement as measured by CD4 + cell counts. None of the symptomatic patients demonstrated a reduction of 12 log 10 copies/mL in virus load during the observation period. In 4 of 7 patients with symptomatic cases, the patients' conditions failed to improve. In 2 of these patients (patients 2 and 3), self-reported nonadherence to therapy for periods varying from 2 weeks to 2 months was noted.
DISCUSSION
HIV-2 is endemic to Africa, where the cost of antiretroviral medications has been prohibitive for most people; thus, there is little experience with the use of antiretroviral regimens for treating HIV-2. The lack of a commercially available HIV-2 virus load assay has also been an obstacle for HIV-2 treatment in all settings. In case studies, zidovudine and other NRTIs have been shown to be effective in treating HIV-2 infection [21, 22] .
As with HIV-1, the earliest methods for monitoring the effectiveness of therapy vis-à-vis HIV-2 were based on clinical, immunologic [23] , and proviral quantitation [22] . Additional methods now include viral phenotypic and genotypic resistance screening and monitoring of virus load. As is the case in patients infected with HIV-1, the development of mutations conferring resistance occurs in patients infected with HIV-2 [24] . The lack of studies undertaken to reveal associations between clinical and virologic parameters and disease or therapeutic efficacy has resulted in uncertainty in the treatment and management of HIV-2-infected patients.
HIV-2, like HIV-1, is a causative agent of AIDS. Although the HIV-2 epidemic is generally limited to West Africa, cases of HIV-2 infection are likely to be seen by physicians outside of this region because of emigration and contact with individuals from regions of endemicity. Individuals infected with HIV-2 in the United States may not immediately receive a correct diagnosis because of clinicians' lack of experience with HIV-2 diagnosis in the United States. In many cases, HIV-2 infection is only discovered after an initial diagnosis of HIV-1, with more discriminating tests being ordered only after other clinical correlates fall outside of expected values (i.e., low CD4 + cell count with undetectable HIV-1 virus load or average CD4 + cell count with low CD4 + cell percentage). This was the case in 3 of 10 patients in our series (patients 3, 7, and 9), for whom a misdiagnosis of HIV-1 infection was discovered as a result of the increasing severity of symptoms and the lack of detection of HIV-1 viremia.
Determining appropriate treatments and laboratory correlates has become more important with the potential for implementing HAART regimens in regions of the world where HIV-2 is endemic. However, treatment of HIV-2 infection remains an uncertain endeavor. Most physicians opt to treat patients with modified HIV-1 HAART regimens, with modifications based on predictions from in vitro studies. NNRTIs have been shown to be largely ineffective against HIV-2 in vitro [25, 26] , whereas NRTIs have been found to be as effective against HIV-2 as they are against HIV-1 in vitro [27] [28] [29] [30] [31] . The development of NRTI resistance in HIV-2 has been reported at positions in the HIV-2 reverse-transcriptase homologous to positions in HIV-1 [32, 33] . In vitro, PIs have mixed effectiveness against HIV-2 [34] . Equal potency against the protease of both viruses has been demonstrated for saquinavir, ritonavir, and nelfinavir, and reduced potency against HIV-2 protease (compared with potency against HIV-1 protease) has been observed with indinavir. Investigation of the variations between the HIV-2 and HIV-1 protease sequences has in part revealed the reasons for differential PI resistance in both virus infections [35] . In at least one study, it has been demonstrated that the resistance mutations in HIV-1 result in sequences more similar to those found in HIV-2 in these homologous regions [36] . This suggests that HIV-2 may possess constitutive PI resistance, suggesting clinical responses to PI-containing regimens may be less effective, compared with the efficacy of these regimens in treating HIV-1 infection.
The majority of patients in our study received several different HAART regimens, most of which included у1 PI. Problems with tolerability and toxicity to the prescribed drugs and poor adherence to the regimens were noted for 4 of 10 patients. In such instances, it is likely that this accounts for the lack of viral suppression as defined by the absence of detectable virus load. In 5 other patients (none of whom reported adherence problems), viral suppression was not observed, despite minor clinical or immunological improvement. Similar results were noted in a recent case series of 18 patients from Ivory Coast [37] . The authors of that study present limited evidence that suggests that indinavir is superior to nelfinavir in controlling virus load.
Although our study is limited by small numbers, the results are surprising and important with respect to HIV-2 clinical management. Prospective natural history studies from West Africa have documented the slower course of disease in individuals infected with HIV-2. In comparison to HIV-1-infected individuals, individuals infected with HIV-2 demonstrate statistically significant lower virus loads during the first 8 years after infection, with ∼30-fold lower virus loads during this time [17] . These data suggest that viral suppression of HIV-2 with antiretroviral drug regimens should be readily achieved. In all 8 patients who demonstrated detectable HIV-2 virus loads and clinical symptomatology, various HAART regimens failed to suppress HIV-2 virus loads below detection. Although HIV-2 virus loads in many of our patients were considered high for HIV-2 infection, such levels would be considered average or low in patients with HIV-1 infection.
Further clinical studies of HIV-2 HAART are clearly warranted. Our preliminary observations suggest that drug regimens with documented efficacy in treating HIV-1 infection may not demonstrate similar efficacy for treatment of HIV-2 infection. Although in vitro studies have demonstrated similar inhibition of virus for most NRTI and PI classes of drugs, the clinical experience noted with these drugs in our described series suggests that further evaluation is required. Controlled clinical trials of HIV-2-infected patients who are receiving various HAART regimens are clearly needed to provide therapeutic guidance to the medical community.
